Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX

NCT01764997 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01764997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01764997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2013
Completion date
January 31, 2015
Enrollment
776 (actual)
Sites
257

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis